The biotech is developing a potential vaccine for the coronavirus. Its pipeline is chock-full of other candidates. Time to buy?
News & Analysis: Inovio Pharmaceuticals
Major indexes have lost about 6% of their value over the past two days.
The COVID-19 respiratory disease is quickly morphing into a pandemic.
The pharmaceutical company received a lot of positive media attention over the weekend.
The COVID-19 virus is putting a wrinkle in the agency's activities.
Investors may want to think twice before buying this vaccine stock on the heels of the COVID-19 threat.
The biotech could start testing its coronavirus vaccine as early as this summer.
The company is starting a new clinical trial, but that may not be the only thing boosting the biotech's shares.
These five biotechs are likely to remain on the volatile side this week, thanks to the novel-coronavirus threat.
Gilead Sciences may be winning the race to develop the first coronavirus treatment.